drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR-T)
drug_description
Autologous gene-modified T cells engineered to express a CAR targeting CD70, eliminating CD70-positive activated B and T lymphocytes (and some APCs) to suppress CD70–CD27–mediated immune activation in MDR-SRNS.
nci_thesaurus_concept_id
C201176
nci_thesaurus_definition
Any preparation of chimeric antigen receptor (CAR) expressing T-lymphocytes that targets the tumor-associated antigen (TAA) CD70.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that binds CD70 on activated B and T lymphocytes (and some APCs). Antigen engagement triggers CAR signaling, leading to T-cell activation and cytotoxic killing (perforin/granzyme and cytokine-mediated) of CD70+ cells, thereby disrupting CD70–CD27 co-stimulation and suppressing pathogenic immune activation in MDR-SRNS.
drug_name
Anti-CD70 CAR-T cells
nct_id_drug_ref
NCT06553898